like drugs may improve kidney disease outcomes
A new study published in the Journal of the American College of Cardiology indicates that semaglutide, commonly known as Ozempic, provides significant kidney protection for patients with type 2 diabetes and chronic kidney disease. The drug was found to improve kidney function and survival rates even in patients with a history of heart issues.
Why it matters
This finding expands the clinical utility of GLP-1 agonists beyond weight loss and diabetes management into critical organ protection.
Semaglutide is a GLP-1 agonist sold under the brand names of Ozempic and Wegovy. ( Reuters: Hollie Adams )
The article reports on medical research findings and clinical guidelines neutrally.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in